- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Antibody Production
- Protein Production
- Protein Characterization
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Newsletter: March 2021
WuXi Biologics Achieve Record High 2020 Results Despite Challenging Year
Facilities and Operations
Remote Pre-Approval Inspection Completed by EMA on WuXi Biologics’ MFG4 Facility Read More
WuXi Biologics Receives GMP Certification from Brazil’s ANVISA Read More
WuXi Biologics to Acquire CMAB and Form Strategic Partnership with CBC Group Read More
WuXi Biologics to Acquire Biologics DS and DP Manufacturing Facilities from Pfizer China Read More
WuXi Biologics to Acquire Drug Substance Facility in Wuppertal, Germany from Bayer Read More
WuXi Vaccines Achieves Weather-Tight Construction Milestone Despite COVID-19 Read More
The World’s Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics Read More
WuXi Biologics Receives GMP Certification from Brazil’s ANVISA Read More
Resources
The Challenge of Staying Current with Regulatory Changes – How one company is providing a solution. View this Podcast
Antibody Drug Conjugates (ADC) Drug Development and Manufacturing Trends, Challenges and Solutions (Webinar)
Expediting Biologics Drug Development: Strategies to Accelerate Preclinical Development Timelines (Webinar)
Applications and Impact of CRISPR/Cas9 in Bioprocessing (Podcast)
Continuous Biomanufacturing Implementation – Using an Intensified and Integrated Bioprocess Platform (White Paper)
The Watershed Moment for ADCs has Arrived – More efficient CMC development is the last barrier (White Paper)
Reducing Fill Risk in Drug Product Manufacture Utilizing New State-of-the-Art Systems and Platforms (Podcast)
New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties And Manufacturability (White Paper)
Scale-Out Biomanufacturing – A Paradigm Change to Scale-Up (White Paper)
Partner News
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline Read More
WuXi Biologics Congratulates Vir Biotechnology on Positive Data from Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Read More
WuXi Biologics, WuXi STA and Antengene Announce Collaboration to Advance Antibody-Drug Conjugate Candidate into Clinical Stage Read More
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform Read More
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation Read More
Awards and Achievements
WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories Read More
WuXi Biologics standardizes a remarkable 12 month “DNA to IND” timeline through its streamlined development platform Read More